Treatment Pathway
Treatment of Giant Cell Arteritis
Giant cell arteritis is inflammation of large and medium arteries in the head. Primarily affecting people over 50, it can cause vision loss if untreated with corticosteroids.
NICE (UK)WHO Clinical GuidelinesAAFP (American Academy of Family Physicians)BMJ Best Practice
Giant cell arteritis is inflammation of large and medium arteries in the head. Primarily affecting people over 50, it can cause vision loss if untreated with corticosteroids.
First-Line Treatment Principles
- ✓Establish confirmed diagnosis before initiating treatment
- ✓Consider patient preferences, comorbidities, and drug interactions when selecting therapy
- ✓Start at lower doses in elderly, renal impairment, or hepatic impairment; titrate to response
- ✓Review treatment indication at regular intervals; deprescribe when indication resolved
- ✓Lifestyle modification as adjunct or first-line for most chronic conditions
Non-Pharmacological Management
- •Diet: evidence-based nutritional approach specific to the condition
- •Regular physical activity: 150 min/week moderate intensity aerobic exercise for most adults
- •Smoking cessation: reduces risk across virtually all disease categories
- •Alcohol restriction: moderate consumption (≤14 units/week) where medically indicated
- •Weight management: maintains BMI 18.5–25 kg/m²
- •Stress management and sleep hygiene
- •Self-management education and patient empowerment
Treatment Goals
🎯Symptom control and quality-of-life improvement
🎯Prevention of complications and disease progression
🎯Minimise treatment burden and adverse effects
🎯Patient-centred shared decision making
Monitoring Parameters
- ◆Condition-specific biomarkers and clinical parameters at each review
- ◆Side effect monitoring according to drug class
- ◆Functional status and quality-of-life assessment
- ◆Treatment adherence: review at every encounter
Escalation Criteria
- →Inadequate response after adequate trial period → second-line therapy or specialist referral
- →Adverse drug reactions or tolerance issues → review and switch therapy
- →Acute deterioration or new complications → emergency assessment
Special Populations
Elderly: polypharmacy risk, renal/hepatic dose adjustments, falls risk assessment
Pregnancy: check safety of all medications; specialist review if on multiple agents
Children: weight-appropriate dosing; developmental monitoring
Not sure about your symptoms?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant treatment pathways.
Use AI Symptom Checker →